Asset Dedication LLC Acquires 314 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Asset Dedication LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,481 shares of the biopharmaceutical company’s stock after purchasing an additional 314 shares during the period. Asset Dedication LLC’s holdings in Gilead Sciences were worth $376,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $25,328,000. Legal & General Group Plc lifted its holdings in shares of Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Gilead Sciences during the 1st quarter worth $462,000. Brookstone Capital Management lifted its holdings in shares of Gilead Sciences by 751.1% during the 1st quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock worth $9,322,000 after acquiring an additional 112,305 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after acquiring an additional 33,162 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research analyst reports. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 9th. Piper Sandler reiterated an “overweight” rating and issued a $95.00 target price on shares of Gilead Sciences in a research report on Wednesday, September 11th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Barclays lifted their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Ten investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $84.83.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 1.1 %

Shares of GILD opened at $86.75 on Thursday. The firm’s 50-day moving average price is $80.56 and its 200-day moving average price is $72.61. The firm has a market capitalization of $108.08 billion, a price-to-earnings ratio of 240.97, a PEG ratio of 2.98 and a beta of 0.18. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.55%. The ex-dividend date was Friday, September 13th. Gilead Sciences’s payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.